Sustained Effects of Interleukin-1 Receptor Antagonist Treatment in Type 2 Diabetes
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Interleukin (IL)-1 impairs insulin secretion and induces β-cell apoptosis. Pancreatic β-cell IL-1 expression is increased and interleukin-1 receptor antagonist (IL-1Ra) expression reduced in patients with type 2 diabetes. Treatment with recombinant IL-1Ra improves glycemia and β-cell function and reduces inflammatory markers in patients with type 2 diabetes. Here we investigated the durability of these responses. RESEARCH DESIGN AND METHODS: Among 70 ambulatory patients who had type 2 diabetes, A1C >7.5%, and BMI >27 kg/m2 and were randomly assigned to receive 13 weeks of anakinra, a recombinant human IL-1Ra, or placebo, 67 completed treatment and were included in this double-blind 39-week follow-up study. Primary outcome was change in β-cell function after anakinra withdrawal. Analysis was done by intention to treat. RESULTS: Thirty-nine weeks after anakinra withdrawal, the proinsulin-to-insulin (PI/I) ratio but not stimulated C-peptide remained improved (by −0.07 [95% CI −0.14 to −0.02], P = 0.011) compared with values in placebo-treated patients. Interestingly, a subgroup characterized by genetically determined low baseline IL-1Ra serum levels maintained the improved stimulated C-peptide obtained by 13 weeks of IL-1Ra treatment. Reductions in C-reactive protein (−3.2 mg/l [−6.2 to −1.1], P = 0.014) and in IL-6 (−1.4 ng/l [−2.6 to −0.3], P = 0.036) were maintained until the end of study. CONCLUSIONS: IL-1 blockade with anakinra induces improvement of the PI/I ratio and markers of systemic inflammation lasting 39 weeks after treatment withdrawal.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“lower levels of IL-1Ra may predict who maintains better β-cell function after an intervention to decrease islet inflammation70.”
From Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future (2014) · cites this paper as [70]
In the citing paper
“This treatment approach for type 2 diabetes is promising, as the improvement in levels of glucose and inflammatory markers was long-lasting110.”
From Sterile inflammation: sensing and reacting to damage (2010) · cites this paper as [110]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Use and Abuse of HOMA Modeling
Wallace, T. M., Levy, J. C., & Matthews, D. R. (2004) · Diabetes Care · doi:10.2337/diacare.27.6.1487 · Cited by 5,114 · cited 1×
“Secondary outcomes included change between baseline and 52 weeks in IL-6, C-reactive protein (CRP), insulin requirements, A1C, and the homeostasis model assessment– insulin sensitivity index (HOMA-Si) (18).”
Backgroundβ-Cell Deficit and Increased β-Cell Apoptosis in Humans With Type 2 Diabetes
Butler, A. E., Janson, J., Bonner-Weir, S., Ritzel, R., Rizza, R. A., & Butler, P. C. (2003) · Diabetes · doi:10.2337/diabetes.52.1.102 · Cited by 4,011
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy
Kahn, S. E., Haffner, S. M., Heise, M. A., Herman, W. H., Holman, R. R., Jones, N. P., Kravitz, B. G., Lachin, J. M., O'Neill, M. C., Zinman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa066224 · Cited by 2,962 · cited 1×
“During the course of the disease beta-cell function progressively declines irrespective of treatment with glucose-lowering drugs (2-4).”
BackgroundU.K. Prospective Diabetes Study Group (1995) · Diabetes · doi:10.2337/diab.44.11.1249 · Cited by 1,923
Interleukin-1-receptor antagonist in type 2 diabetes mellitus
Larsen, C. M., Faulenbach, M., Vaag, A., Vølund, A., Ehses, J. A., Seifert, B., Mandrup-Poulsen, T., & Donath, M. Y. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065213 · Cited by 1,798 · cited 6×
“At baseline, and at 13 and 52 weeks, beta-cell secretory function was assessed by the fasting PI/I ratio and by a 2-hour oral glucose-tolerance test directly followed by a 12-minute intravenous glucose, glucagon and arginine stimulation test as described previously (16).”
BackgroundMethodResultInfluentialSelf-citationGlucose-induced β cell production of IL-1β contributes to glucotoxicity in human pancreatic islets
Maedler, K., Sergeev, P., Ris, F., Oberholzer, J., Joller-Jemelka, H. I., Spinas, G. A., Kaiser, N., Halban, P. A., & Donath, M. Y. (2017) · Journal of Clinical Investigation · doi:10.1172/jci92172 · Cited by 1,114
Self-citationGlucose-induced β cell production of IL-1β contributes to glucotoxicity in human pancreatic islets
Maedler, K., Sergeev, P., Ris, F., Oberholzer, J., Joller-Jemelka, H. I., Spinas, G. A., Kaiser, N., Halban, P. A., & Donath, M. Y. (2002) · Journal of Clinical Investigation · doi:10.1172/jci200215318 · Cited by 1,005
Self-citationDiagnosis and Classification of Diabetes Mellitus
American Diabetes Association (2006) · Diabetes Care · doi:10.2337/diacare.29.s1.06.s43 · Cited by 924
Increased Number of Islet-Associated Macrophages in Type 2 Diabetes
Ehses, J. A., Perren, A., Eppler, E., Ribaux, P., Pospisilik, J. A., Maor-Cahn, R., Gueripel, X., Ellingsgaard, H., Schneider, M. K. J., Biollaz, G., et al. (2007) · Diabetes · doi:10.2337/db06-1650 · Cited by 783 · cited 1×
“IL-1 production could thus originate from the betacell (7) or from macrophages infiltrating the islets (23) as the IL-1B gene is overexpressed in blood monocytes from patients with type 2 diabetes (24).”
BackgroundSelf-citation
Cited by
Items 201–300 of 407
Arous, C., Ferreira, P. G., Dermitzakis, E. T., & Halban, P. A. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.611111 · Cited by 35
“Although pilot studies in type 2 diabetes proved successful (6, 7), such was not the case for type 1 diabetes (8).”
BackgroundDiabetes treatment in 2025: can scientific advances keep pace with prevalence?
Shomali, M. E. (2012) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018812465639 · Cited by 40
Obesity development in caspase-1-deficient mice
Wang, H., Capell, W. H., JiSun, Y. O. O. N., Faubel, S. G., & Eckel, R. H. (2013) · International Journal of Obesity · doi:10.1038/ijo.2013.59 · Cited by 39
Salah, N., Dubuquoy, L., Carpentier, R., & Betbeder, D. (2022) · International Journal of Pharmaceutics X · doi:10.1016/j.ijpx.2022.100114 · Cited by 36
“, 2012) and leading to acute and chronic inflammation (Halle et al., 2008; Larsen et al., 2009).”
BackgroundBellucci, P. N., Bagnes, M. F. G., Girolamo, G. D., & González, C. D. (2016) · Journal of Pharmacy Practice · doi:10.1177/0897190016649551 · Cited by 34
The Emerging Role of Interleukin-1β in Autoinflammatory Diseases
Lane, T., & Lachmann, H. J. (2011) · Current Allergy and Asthma Reports · doi:10.1007/s11882-011-0207-6 · Cited by 38
“Studies have shown that IL-1 blockade using anakinra not only reduced levels of inflammatory markers but also improved B-cell function and glycemic control [76], and that this response is sustained for at least 36 weeks [77].”
BackgroundAlpha cells, the main source of IL-1β in human pancreas
Anquetil, F., Sabouri, S., Thivolet, C. H., Calvo, T. R., Zapardiel‐Gonzalo, J., Amirian, N., Schneider, D., Castillo, E., Lajevardi, Y., & von Herrath, M. G. (2017) · Journal of Autoimmunity · doi:10.1016/j.jaut.2017.03.006 · Cited by 37
“However, it only provided transient benefits since HBA1c reduction was not sustainable after one year [15].”
BackgroundResultCirculating Biomarkers of Inflammation and Endothelial Activation in Diabetic Retinopathy
Storti, F., Pulley, J., Kuner, P., Abt, M., & Luhmann, U. F. O. (2021) · Translational Vision Science & Technology · doi:10.1167/tvst.10.12.8 · Cited by 33
Urizar, A. I., Prause, M. C. B., Wortham, M., Sui, Y., Thams, P., Sander, M., Christensen, G. L., & Billestrup, N. (2019) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2019.110524 · Cited by 33
“However, therapies targeting IL-1β have shown diverse results in different clinical trials (van Asseldonk et al., 2011; Larsen et al., 2009; Ramos-Zavala et al., 2011).”
BackgroundAnti-NLRP3 Inflammasome Natural Compounds: An Update
Liu, B., & Yu, J. (2021) · Biomedicines · doi:10.3390/biomedicines9020136 · Cited by 36
Zhu, J., Han, J., Liu, L., Liu, Y., Xu, W., Li, X., Yang, L., Gu, Y., Tang, W., Shi, Y., et al. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110568 · Cited by 34
Targeting IL-1 in Sjögren's syndrome
Yamada, A., Arakaki, R., Kudo, Y., & Ishimaru, N. (2013) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2013.754427 · Cited by 33
“Furthermore, many clinical approaches with IL-1 blockade for various diseases have been tried, including stroke, type 1and 2 diabetes, multiple sclerosis and so on [76-79,68].”
BackgroundMandrup-Poulsen, T. R. (2013) · Dermatologic Clinics · doi:10.1016/j.det.2013.04.006 · Cited by 34
Self-citationClinical Potential of Extracellular Vesicles in Type 2 Diabetes
Liu, J., Sun, X., Zhang, F.-L., Jin, H., Yan, X., Huang, S., Guo, Z., & Yang, Y. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.596811 · Cited by 31
Mechanisms and therapeutic potential of pharmacological agents targeting inflammasomes
Li, H., Liu, T., Shi, X., Du, H., Cai, C., Yang, D., Qu, L., Dou, H., Jiao, B., & Jiao, B. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118164 · Cited by 32
Gaetano, A. D., & Hardy, T. A. (2019) · PLoS ONE · doi:10.1371/journal.pone.0222833 · Cited by 30
“[13] used our previously published model [10] as a basis for focusing on the effect of IL-1β (Inter-Leukin -1 β) inhibitors such as anakinra [15, 16].”
MethodPeripheral CB1R as a modulator of metabolic inflammation
Han, J. H., & Kim, W. (2021) · The FASEB Journal · doi:10.1096/fj.202001960r · Cited by 31
Effect of the IL-1 Receptor Antagonist Kineret® on Disease Phenotype in mdx Mice
Klimek, M. B., Sali, A., Rayavarapu, S., van der Meulen, J. H., & Nagaraju, K. (2016) · PLoS ONE · doi:10.1371/journal.pone.0155944 · Cited by 29
Inflammatory stress in islet β-cells: therapeutic implications for type 2 diabetes?
Lytrivi, M., Igoillo‐Esteve, M., & Cnop, M. (2018) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2018.08.002 · Cited by 30
El-Shemi, A. G., Kensara, O. A., Alsaegh, A., & Mukhtar, M. H. (2017) · Pharmacology · doi:10.1159/000480018 · Cited by 30
A Positive Causal Influence of IL-18 Levels on the Risk of T2DM: A Mendelian Randomization Study
Zhuang, H., Han, J., Cheng, L., & Liu, S. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.00295 · Cited by 29
Should we treat infection or inflammation to prevent T2DM?
Vaarala, O., & Yki‐Järvinen, H. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.31 · Cited by 28
Altered islet prohormone processing: a cause or consequence of diabetes?
Ramzy, A., & Kieffer, T. J. (2021) · Physiological Reviews · doi:10.1152/physrev.00008.2021 · Cited by 32
Misaki, Y., Miyauchi, R., Mochizuki, K., Takabe, S., Shimada, M., Ichikawa, Y., & Goda, T. (2010) · Metabolism · doi:10.1016/j.metabol.2010.01.011 · Cited by 28
Santalahti, K., Maksimow, M., Airola, A., Pahikkala, T., Hutri‐Kähönen, N., Jalkanen, S., Raitakari, O. T., & Salmi, M. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2081 · Cited by 29
Ursini, F., Russo, E., Ruscitti, P., Giacomelli, R., & Sarro, G. D. (2018) · Autoimmunity Reviews · doi:10.1016/j.autrev.2017.11.030 · Cited by 26
Molecular Basis of Selective Cytokine Signaling Inhibition by Antibodies Targeting a Shared Receptor
Fields, J. K., Kihn, K. C., Birkedal, G. S., Klontz, E. H., Sjöström, K., Günther, S., Beadenkopf, R., Forsberg, G., Liberg, D., Snyder, G. A., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.779100 · Cited by 26
Wang, H., Kang, P., Wu, W., Tang, Y., PAN, Q.-Q., Ye, H., Tang, B., Li, Z., & Gao, Q. F. (2013) · Molecular Medicine Reports · doi:10.3892/mmr.2013.1524 · Cited by 26
Rheumatoid Arthritis Treatment Options and Type 2 Diabetes: Unravelling the Association
Muzio, C. D., Cipriani, P., & Ruscitti, P. (2022) · BioDrugs · doi:10.1007/s40259-022-00561-7 · Cited by 28
“Interestingly, comparing these findings to the previous studies on T2D following administration of bDMARDs [97, 98, 100, 101], a more evident reduction of HbA1c has been observed in patients with RA and concomitant T2D (Table 1), mainly considering results about IL-1 inhibition.”
BackgroundResultPreservation of Beta-Cell Function in Type 2 Diabetes
Nyalakonda, K., Sharma, T., & Ismail‐Beigi, F. (2010) · Endocrine Practice · doi:10.4158/ep10112.ra · Cited by 27
Vilahur, G., López-Bernal, S., Camino-López, S., Mendieta, G., Padró, T., & Badimón, L. (2014) · European Journal of Nutrition · doi:10.1007/s00394-014-0794-9 · Cited by 30
“In addition, clinical trials with antagonists of IL-1 receptor for the treatment of T2D have evidenced NLRP3 inflammasome as a sensor of metabolic stress [49, 50].”
BackgroundAnghel, F. M., Matei, S.-C., Olteanu, G., Barna, R. A., & Marian, C. (2025) · Biomedicines · doi:10.3390/biomedicines13123050 · Cited by 24
The human serum protein C4b-binding protein inhibits pancreatic IAPP-induced inflammasome activation
Kułak, K. B., Westermark, G. T., Papac-Miličević, N., Renström, E., Blom, A. M., & King, B. C. (2017) · Diabetologia · doi:10.1007/s00125-017-4286-3 · Cited by 25
“The cytokine IL-1β plays an important role, and IL-1βtargeted therapy has shown promise in animal models [2] and clinical trials [3, 4].”
BackgroundLeiva-Valderrama, J. M., Montes‐de‐Oca‐García, A., Opazo‐Díaz, E., Ponce‐González, J. G., Molina‐Torres, G., Velázquez‐Díaz, D., & Galán-Mercant, A. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph182312644 · Cited by 24
Chen, C., Chen, Y., Gao, Q., & Wei, Q. (2023) · BMC Cardiovascular Disorders · doi:10.1186/s12872-023-03638-5 · Cited by 25
“Studies have demonstrated that anti-inflammatory therapy in diabetes could improve glycemia and increase insulin secretion [24–26].”
BackgroundIslet inflammation in plain sight
Abdulreda, M. H., & Berggren, P. (2013) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12160 · Cited by 23
“Moreover, in vitro and in vivo studies show that targeting the STAT1 pathway yields protective effects on β-cells in diabetic animal models and improves β-cell survival in isolated rodent and human islets [24,25].”
BackgroundLambadiari, V., Kousathana, F., Raptis, A. E., Katogiannis, K., Kokkinos, A. D., & Ikonomidis, I. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.557235 · Cited by 23
“A common therapeutic approach to SARS-CoV-2 complications (5) and type 2 diabetes with IL-1 blockade agents (44) can strengthen the suggestion of the association of type 2 diabetes and COVID-19 complications.”
BackgroundFunctional and Mechanistic Integration of Infection and the Metabolic Syndrome
Sommer, P., & Sweeney, G. (2010) · Korean Diabetes Journal · doi:10.4093/kdj.2010.34.2.71 · Cited by 23
“The therapeutic potential of targeting the mechanisms outlined above are reinforced by the recent promise of IL-1B receptor antagonism in clinical trials for the treatment of diabetes [20,21].”
BackgroundExploring the Interplay between Fatty Acids, Inflammation, and Type 2 Diabetes
Nicholas, D., Mbongue, J. C., Garcia-Pérez, D., Sorensen, D. W., Bennit, H. R. F., León, M. A. D., & Langridge, W. H. R. (2024) · Immuno · doi:10.3390/immuno4010006 · Cited by 26
“These effects lasted up to 39 weeks post withdrawal from the medication [115].”
Timper, K., Seelig, E., Tsakiris, D. A., & Donath, M. Y. (2015) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2015.05.019 · Cited by 22
Self-citationNyman, E., Wesseling-Rozendaal, Y. J. W., Helmlinger, G., Hamrén, B., Kjellsson, M. C., Strålfors, P., van Riel, N. A. W., Gennemark, P., & Cedersund, G. (2016) · Interface Focus · doi:10.1098/rsfs.2015.0075 · Cited by 24
“Simulation results were compared with observed clinical effects of the drug anakinra [57,58] (figure 3).”
MethodResultEndothelial Dysfunction in Type 2 Diabetes: Targeting Inflammation
Sena, C. M., Carrilho, F., & Seiça, R. M. F. (2018) · InTech eBooks · doi:10.5772/intechopen.76994 · Cited by 27
“Additionally, randomized, placebo-controlled, double-masked clinical trials of salsalate [ 99 , 100], IL1Ra [101, 102] and anti-TNF-α [103 ] are being used to determine whether these anti-inflammatory approaches modify disease risk in type 2 diabetes and atherosclerotic cardiovascular disease.”
MethodIntracellular Function of Interleukin-1 Receptor Antagonist in Ischemic Cardiomyocytes
Vecile, E., Dobrina, A., Salloum, F. N., Tassell, B. W. V., Falcione, A., Gustini, E., Secchiero, S., Crovella, S., Sinagra, G., Finato, N., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0053265 · Cited by 21
“Recently, Larsen et al. (2009) [37] reported that treatment with recombinant IL-1Ra caused a significant and long lasting improvement of b-cell function in type II diabetic patients bearing a IL-1Ra gene polymorphism associated to reduced IL-1Ra b-cell expression.”
BackgroundInterleukin-1: Ariadne's Thread in Autoinflammatory and Autoimmune Disorders.
Cantarini, L., Lopalco, G., Cattalini, M., Vitale, A., Galeazzi, M., & Rigante, D. (2015) · PubMed · Cited by 23
Interleukin 1β: A Proinflammatory Target for Preventing Atherosclerotic Heart Disease
McCarty, S., & Frishman, W. H. (2014) · Cardiology in Review · doi:10.1097/crd.0000000000000022 · Cited by 20
Aftabizadeh, M., Tatarek‐Nossol, M., Andreetto, E., Bounkari, O. E., Kipp, M., Beyer, C., Latz, E., Bernhagen, J., & Kapurniotu, A. (2019) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.9b00260 · Cited by 22
Nrf2 in the Field of Dentistry with Special Attention to NLRP3
Schieffer, L., Manzl, C., Schatz, C., Haybaeck, J., & Crismani, A. G. (2022) · Antioxidants · doi:10.3390/antiox11010149 · Cited by 22
“NLRP3 has been the object of numerous studies in which g in-of-function mutations have been associated with various diseases characterized by the pathogenesis of inflammatory disorders, including gout, type 2 diabetes, and atherosclerosis [28,29].”
BackgroundInterleukin-1 Antagonists and Other Cytokine Blockade Strategies for Type 1 Diabetes
Mandrup-Poulsen, T. R. (2012) · The Review of Diabetic Studies · doi:10.1900/rds.2012.9.338 · Cited by 21
Self-citationPalmér, R., Nyman, E., Penney, M., Marley, A., Cedersund, G., & Agoram, B. M. (2014) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1038/psp.2014.16 · Cited by 19
“5,6 to describe local antagonist and IL-1 β concentrations during and after anakinra treatment.”
InfluentialKoufakis, T., Dimitriadis, G., Metallidis, S., Zebekakis, P. E., & Kotsa, K. (2021) · Obesity Reviews · doi:10.1111/obr.13231 · Cited by 22
Role of the Pancreatic Islet Microvasculature in Health and Disease
Aplin, A. C., Aghazadeh, Y., Mohn, O. G., & Hull, R. L. (2024) · Journal of Histochemistry & Cytochemistry · doi:10.1369/00221554241299862 · Cited by 22
“Some, 146,147 but not all studies, 148,149 showed a beneficial effect, suggesting blockade of IL-1 alone may not be sufficient to improve beta-cell function in people living with T2D.”
Bihorel, S., Fiedler‐Kelly, J., Ludwig, E. A., Sloan‐Lancaster, J., & Raddad, E. (2014) · The AAPS Journal · doi:10.1208/s12248-014-9623-6 · Cited by 19
Something old, something new and something very old: drugs for treating type 2 diabetes
Kaiser, D., & Oetjen, E. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12624 · Cited by 24
“In a 39 week follow-up study, the antiinflammatory effect of anakinra was still present, whereas the improvement in HbA1c levels was no longer detectable (Larsen et al., 2009).”
BackgroundMacrophages and Lymphocytes: Nature, Functions, and Interaction
(1980) · Advances in experimental medicine and biology · doi:10.1007/978-1-4684-8914-9 · Cited by 20
Arefin, A., & Gage, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054785 · Cited by 17
Small‐molecule inhibition of inflammatory β ‐cell death
Lundh, M., Scully, S. S., Mandrup-Poulsen, T. R., & Wagner, B. K. (2013) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12158 · Cited by 17
“Furthermore, a 39-week follow-up study showed that most effects were sustained in responders [15].”
BackgroundSelf-citationThe multifaceted role of profilin-1 in adipose tissue inflammation and glucose homeostasis
Pae, M., & Romeo, G. R. (2013) · Adipocyte · doi:10.4161/adip.26965 · Cited by 19
“Abbreviations: PIP2, phosphoinositides 4,5-bisphosphate; VASP, vasodilator-stimulated phosphoprotein. www.landesbioscience.com Adipocyte 71 endothelium of streptozotocin-diabetic rats, in endothelial cells (EC) exposed to oxidized cholesterol or oxidized LDL— but not to high glucose concentrations— and in atherosclero…”
BackgroundInfluentialFields, J. K., Gyllenbäck, E. J., Bogacz, M., Obi, J. O., Birkedal, G. S., Sjöström, K., Maravillas, K., Grönberg, C., Rattik, S., Kihn, K. C., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114099 · Cited by 17
Renal AA Amyloidosis in Patients with Type 2 Diabetes Mellitus
Díez, R., Madero, M., Gamba, G., Soriano, J., & Soto, V. (2014) · Nephron Extra · doi:10.1159/000363625 · Cited by 19
Unraveling the Pathogenesis of the Depression–Diabetes Link
Ismail, K. (2010) · Wiley eBooks · doi:10.1002/9780470667309.ch2 · Cited by 20
Lipid mediators and inflammation in glucose intolerance and insulin resistance
Iyer, A., & Brown, L. (2010) · Drug Discovery Today Disease Mechanisms · doi:10.1016/j.ddmec.2010.12.001 · Cited by 18
Immunomodulation by helminths: Similar impact on type 1 and type 2 diabetes?
Surendar, J., Indulekha, K., Hoerauf, A. M., & Hübner, M. P. (2016) · Parasite Immunology · doi:10.1111/pim.12401 · Cited by 19
Zhao, L., Li, J., Xu, X., Zhang, N., He, T., Yuan, Y., Zhang, Y., & Li, H. (2024) · Cell Reports Physical Science · doi:10.1016/j.xcrp.2024.102147 · Cited by 16
Lyngbæk, M. P. P., Legaard, G. E., Bennetsen, S. L., Feineis, C. S., Rasmussen, V., Moegelberg, N., Brinkløv, C. F., Nielsen, A. B., Kofoed, K. S., Lauridsen, C. A., et al. (2021) · Trials · doi:10.1186/s13063-021-05207-7 · Cited by 16
“Indeed, 13 weeks of pharmacological inhibition of IL1-β in T2D patients by subcutaneous injections of the IL-1 receptor antagonist (IL-1RA) did increase β-cell secretory function [29].”
BackgroundApplication of Ultrasound Localization Microscopy in Evaluating the Type 2 Diabetes Progression
Zhang, T., Yan, J.-P., Zhou, X.-H., Wu, B.-H., Zhang, C., Tang, M.-X., & Huang, P.-T. (2024) · Cyborg and Bionic Systems · doi:10.34133/cbsystems.0117 · Cited by 13
“The anti-cytokine immunotherapy of type 2 diabetes is a new treatment method in recent years, especially blocking IL-1 β in the process of impaired insulin secretion and insulin resistance, and can be used as a potential therapeutic target to reverse the quality and function of β cells [ 44 – 46 ].”
Mikkelsen, R. R., Hundahl, M. P., Torp, C. K., Rodríguez‐Carrio, J., Kjølby, M., Bruun, J. M., & Kragstrup, T. W. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.174998 · Cited by 16
Adipose tissue NLRP3 inflammasome: a therapeutic target in obesity and type 2 diabetes mellitus
Nnolum-Orji, N. F., Kumar, P., Ngema, L. M., & Choonara, Y. E. (2025) · Drug Discovery Today · doi:10.1016/j.drudis.2025.104456 · Cited by 13
Antigen-based vs. systemic immunomodulation in type 1 diabetes: The pros and cons
Robert, S., Korf, H., Gysemans, C. A., & Mathieu, C. (2013) · Islets · doi:10.4161/isl.24785 · Cited by 16
Incretins: B eyond type 2 diabetes
Dandona, P., Ghanim, H., & Chaudhuri, A. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13153 · Cited by 14
“results in an improvement in glycemia through an improvement in β-cell function and insulinogenesis.(89,90) Thus, the anti-inflammatory actions of linagliptin and other mem-”
BackgroundDiabetes in COVID-19 patients: challenges and possible management strategies
Reshad, R. A. I., Riana, S. H., Chowdhury, M. A.-B., Moin, A. T., Miah, F., Sarkar, B., & Jewel, N. A. (2021) · Egyptian Journal of Bronchology · doi:10.1186/s43168-021-00099-2 · Cited by 15
Interleukin-1 antagonists for diabetes
Mandrup-Poulsen, T. R. (2013) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2013.804060 · Cited by 13
Self-citationGevokizumab in type 1 diabetes mellitus: extreme remedies for extreme diseases?
Pafili, K., Παπάνας, Ν., & Maltezos, E. S. (2014) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2014.947026 · Cited by 13
“Of note, there was no significant change in body weight or laboratory parameters, such as aminotransferases or creatinine [63].”
BackgroundInfluentialDual Inhibition of Interleukin-1β and Interleukin-18: A New Treatment Option for Sepsis?
Opal, S. M. (2014) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201312-2292ed · Cited by 13
Kolb, H., Lückemeyer, K., Heise, T., Herder, C., Schloot, N. C., Köenig, W., Heinemann, L., Martin, S., & on behalf of the DIATOR Study Group (2013) · PLoS ONE · doi:10.1371/journal.pone.0072440 · Cited by 12
“Down regulation of systemic inflammation by treatment with IL-1RA was also observed in patients with long standing type 2 diabetes, and there was significant preservation of residual beta cell function, lasting for at least 9 months after the end of treatment, in the majority of patients [33,34].”
BackgroundIL ‐1 receptor antagonist levels are associated with glucose tolerance in polycystic ovary syndrome
Luotola, K., Piltonen, T., Puurunen, J., & Tapanainen, J. S. (2016) · Clinical Endocrinology · doi:10.1111/cen.13077 · Cited by 12
Jangsiripornpakorn, J., Srisuk, S., Chailurkit, L., Nimitphong, H., Saetung, S., & Ongphiphadhanakul, B. (2022) · BMC Research Notes · doi:10.1186/s13104-022-05974-9 · Cited by 12
“Previous studies have demonstrated that anti-inflammation treatments in T2DM such as anakinra [10, 11] and gevokizumab [12], decrease CRP levels which correlate with the reduction in HbA1c levels and improvement in insulin secretion [13, 14].”
BackgroundOh, Y. T., Tran, D., Buchanan, T. A., Selsted, M. E., & Youn, J. H. (2015) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00131.2015 · Cited by 12
When diet and exercise are not enough, think immunomodulation
Snyder-Cappione, J. E., & Nikolajczyk, B. S. (2012) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2012.10.003 · Cited by 11
Oxidative Modification, Inflammation and Amyloid in the Normal and Diabetic Cat Pancreas
Herndon, A., Breshears, M. A., & McFarlane, D. (2014) · Journal of Comparative Pathology · doi:10.1016/j.jcpa.2014.06.004 · Cited by 13
The Role of Interleukin-1β in Destruction of Transplanted Islets
Chen, C., Rong, P., Yang, M. H., Ma, X., Feng, Z., & Wang, W. (2020) · Cell Transplantation · doi:10.1177/0963689720934413 · Cited by 12
Jensen, T. S. R., Binderup, T., Olsen, M. H., Kjær, A., & Fugleholm, K. (2023) · Inflammation · doi:10.1007/s10753-023-01811-8 · Cited by 10
The role of IL-1 family cytokines in diabetic cardiomyopathy
Wu, Q., Zeng, Y., Geng, K., Guo, M., Teng, F., Yan, P., Lei, Y., Long, Y., Jiang, Z., Law, B. Y. K., et al. (2024) · Metabolism · doi:10.1016/j.metabol.2024.156083 · Cited by 13
Kalb, D. M., Adikari, S., Hong‐Geller, E., & Werner, J. H. (2019) · PLoS ONE · doi:10.1371/journal.pone.0215602 · Cited by 9
Drug discovery for type 2 diabetes mellitus and metabolic syndrome: ten novel biological targets
Tyurenkov, I. N., Куркин, Д. В., Волотова, Е. В., Bakulin, D. A., & Lomkina, E. M. (2015) · Diabetes Mellitus · doi:10.14341/dm20151101-109 · Cited by 10
Marcuzzi, A., Piscianz, E., Valencic, E., Monasta, L., Brumatti, L. V., & Tommasini, A. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms160921277 · Cited by 10
Autoinflammatory Disorders, Pain, and Neural Regulation of Inflammation
Chen, M. C., & Meckfessel, M. (2013) · Dermatologic Clinics · doi:10.1016/j.det.2013.04.002 · Cited by 9
Liu, Z., Wang, M., Liu, Y., Ren, M., Xi, X., Li, S., & Kang, W. (2023) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2023/9069645 · Cited by 10
Interleukin-1 receptor antagonist: From synthesis to therapeutic applications
Rehman, K., Afzaal, A., Akash, M. S. H., Imran, M., & Assiri, M. A. (2023) · Biocell · doi:10.32604/biocell.2023.025850 · Cited by 8
Immune-Modulating Therapy for Rheumatologic Disease: Implications for Patients with Diabetes
Pilla, S. J., Quan, A. Q., Germain‐Lee, E. L., Hellmann, D. B., & Mathioudakis, N. N. (2016) · Current Diabetes Reports · doi:10.1007/s11892-016-0792-9 · Cited by 9
Mochizuki, K., Misaki, Y., Miyauchi, R., Takabe, S., Shimada, M., Miyoshi, N., Ichikawa, Y., & Goda, T. (2010) · Metabolism · doi:10.1016/j.metabol.2010.08.011 · Cited by 7
“Treatment of diabetic patients with anakinra, a recombinant human IL-1Ra developed as a drug for rheumatoid arthritis, improved the glycemic status, maintained high C-peptide secretion, and reduced plasma IL-6 levels [30,31].”
BackgroundNew avenues for the pharmacological management of type 2 diabetes: An update
Cuny, T., Guerci, B., & Cariou, B. (2012) · Annales d Endocrinologie · doi:10.1016/j.ando.2012.09.002 · Cited by 7
Type 2 Diabetes, Immunity and Cardiovascular Risk: A Complex Relationship
Pedicino, D., Francesca, A., Alessandro, V., Trotta, F., & Liuzzo, G. (2012) · InTech eBooks · doi:10.5772/50611 · Cited by 7
“…and decompensated insulin secretion, has prompted the use of anakinra in a double-blind clinical trial in patients with T2DM, that showed an improvement in β -cell secretory function, glycemia and inflammatory markers both during treatment and after drug withdrawal (Larsen et al., 2007, 2009).”
Documentation of off-label use of biologics in Rheumatoid Arthritis
Fürst, D. E., Fleischman, R., Kalden, J. R., Kavanaugh, A., Sieper, J., Mease, P. J., Smolen, J. S., & Breedveld, F. C. (2013) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-consensusapp · Cited by 7
Tipping-point transition from transient to persistent inflammation in pancreatic islets
Holst‐Hansen, T., Yde, P., Jensen, M. H., Mandrup-Poulsen, T. R., & Trusina, A. (2024) · npj Systems Biology and Applications · doi:10.1038/s41540-024-00427-4 · Cited by 6
“Other studies targeted the increased level of cytokines through IL-1 β antibodies, with a similar improvement of β -cell function and lowered in fl ammation 39,40 .”
BackgroundSelf-citationGuan, J., Abudouaini, H., Lin, K., & Yang, K. (2024) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-024-01369-x · Cited by 10
“The patient group demonstrated a better blood proinsulin/insulin ratio, lower CRP, and IL-6 levels even thirty-nine weeks after stopping anakinra treatment, however there was no difference in HbA1c levels [16].”
BackgroundResultRetractedWieser, V. E., Moschen, A. R., & Tilg, H. (2014) · Humana Press eBooks · doi:10.1007/978-1-62703-770-9_7 · Cited by 6
The Connexin 43 Regulator Rotigaptide Reduces Cytokine-Induced Cell Death in Human Islets
Ghiasi, S. M., Hansen, J. B., Christensen, D. P., Tyrberg, B., & Mandrup-Poulsen, T. R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124311 · Cited by 6
“an effect sustained 39 weeks beyond cessation of the antagonism in responders [3].”
BackgroundSelf-citationLiu, W., Zhao, W., Lai, J., Shen, Q., Xu, Y., Pan, L., & Chen, S. (2016) · Biotechnology and Applied Biochemistry · doi:10.1002/bab.1532 · Cited by 6
Tassell, B. W. V. (2015) · Journal of Clinical Trials in Cardiology · doi:10.15226/2374-6882/2/2/00122 · Cited by 5
Leahy, J. L., & Pratley, R. E. (2011) · Translational endocrinology & metabolism · doi:10.1210/team.9781879225824.ch1 · Cited by 9
Metadata
- Authors
- Larsen, C. M., Faulenbach, M., Vaag, A., Ehses, J. A., Donath, M. Y., & Mandrup-Poulsen, T.
- Affiliations
- Hagedorn Research Institute and Steno Diabetes Center, Gentofte, Denmark;
- University Hospital Zurich (CH)
- Lund University (SE)
- University of Copenhagen (DK)
- Corresponding author
- Mandrup-Poulsen, Thomas
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2009-06-19
- Volume
- 32
- Issue
- 9
- Pages
- 1663-1668
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC2732140
- OpenAlex
- W2137334382
- Cited by
- 401
- References
- 28
- Citations by year
- 2026: 5 · 2025: 8 · 2024: 27 · 2023: 15 · 2022: 14 · 2021: 28 · 2020: 16 · 2019: 21 · 2018: 11 · 2017: 23 · 2016: 21 · 2015: 27 · 2014: 36 · 2013: 42 · 2012: 32
- FWCI
- 35.76
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
- Lund University Publications (Lund University) (submittedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Keywords
- interleukin-1 receptor antagonist, anakinra, type 2 diabetes, beta-cell function, insulin secretion, beta-cell apoptosis, IL-1 blockade, C-peptide, proinsulin/insulin ratio, C-reactive protein, interleukin-6, systemic inflammation, treatment withdrawal, glycemic control
- MeSH terms
- Diabetes Mellitus, Type 2, Female, Humans, Male, Antirheumatic Agents, Insulin-Secreting Cells, Interleukin 1 Receptor Antagonist Protein, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.